The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -0.29 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.38 — no flag raisedOK
- Earnings quality 45/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Tonix Pharmaceuticals Holding Corp. reports it. History and quarterly detail are in the app.
- Zembrace Symtouch$9.3M
- Tosymra$2.4M
- Tonmya$1.4M
Leadership changes
From Tonix Pharmaceuticals Holding Corp.'s own filings, the day they're filed.
- Siobhan Fogarty · Chief Technology Officer · appointmenteff. 2025-02-03
- James Hunter · Chief Executive Officer · appointment
- Pharmaceutical Science · director · appointment
Latest filings
- 8-K · Company announcement2026-08-18
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-21
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Tonix Pharmaceuticals Holding Corp., every answer cited to the official filings🔒
- The Intelligence Brief — added when Tonix Pharmaceuticals Holding Corp.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.